| Primary |
| Systemic Lupus Erythematosus |
20.6% |
| Product Used For Unknown Indication |
17.6% |
| Rheumatoid Arthritis |
11.8% |
| Cutaneous Lupus Erythematosus |
8.8% |
| Drug Use For Unknown Indication |
5.9% |
| Malaria |
5.9% |
| Malaria Prophylaxis |
5.9% |
| Discoid Lupus Erythematosus |
2.9% |
| Fungal Infection |
2.9% |
| Hepatic Amoebiasis |
2.9% |
| Mixed Connective Tissue Disease |
2.9% |
| Off Label Use |
2.9% |
| Pyrexia |
2.9% |
| Sjogren's Syndrome |
2.9% |
| Vasculitis |
2.9% |
|
| Toxicity To Various Agents |
15.4% |
| Ventricular Hypertrophy |
11.5% |
| Ventricular Tachycardia |
7.7% |
| Acquired Pigmented Retinopathy |
3.8% |
| Cardiomyopathy |
3.8% |
| Cardiotoxicity |
3.8% |
| Cerebellar Ataxia |
3.8% |
| Dizziness |
3.8% |
| Epilepsy |
3.8% |
| Grand Mal Convulsion |
3.8% |
| Hypochromic Anaemia |
3.8% |
| Maculopathy |
3.8% |
| Mania |
3.8% |
| Psychotic Disorder |
3.8% |
| Retinopathy |
3.8% |
| Scotoma |
3.8% |
| Suicidal Ideation |
3.8% |
| Syncope |
3.8% |
| Transaminases Increased |
3.8% |
| Troponin Increased |
3.8% |
|
| Secondary |
| Product Used For Unknown Indication |
59.2% |
| Rheumatoid Arthritis |
9.8% |
| Asthma |
5.2% |
| Lupus Nephritis |
4.6% |
| Systemic Lupus Erythematosus |
2.6% |
| Drug Exposure During Pregnancy |
2.3% |
| Juvenile Arthritis |
2.0% |
| Hypertension |
1.7% |
| Dermatomyositis |
1.4% |
| Malaria |
1.1% |
| Malaria Prophylaxis |
1.1% |
| Overdose |
1.1% |
| Plasmodium Falciparum Infection |
1.1% |
| Pyrexia |
1.1% |
| Suicide Attempt |
1.1% |
| Epilepsy |
0.9% |
| Hiv Test Positive |
0.9% |
| Hyperlipidaemia |
0.9% |
| Mixed Connective Tissue Disease |
0.9% |
| Multiple Myeloma |
0.9% |
|
| Drug Exposure During Pregnancy |
12.1% |
| Death |
9.1% |
| Drug Hypersensitivity |
6.1% |
| Drug Interaction |
6.1% |
| Hypochromic Anaemia |
6.1% |
| Hypotension |
6.1% |
| Sepsis |
6.1% |
| Ventricular Tachycardia |
6.1% |
| Visual Field Defect |
6.1% |
| Vomiting |
6.1% |
| Abnormal Dreams |
3.0% |
| Abortion Spontaneous |
3.0% |
| Chest Pain |
3.0% |
| Completed Suicide |
3.0% |
| Cytolytic Hepatitis |
3.0% |
| Diverticulitis |
3.0% |
| Dyspnoea Exertional |
3.0% |
| Electrocardiogram Qt Prolonged |
3.0% |
| Erosive Duodenitis |
3.0% |
| Eye Disorder |
3.0% |
|
| Concomitant |
| Rheumatoid Arthritis |
38.5% |
| Product Used For Unknown Indication |
32.0% |
| Hypertension |
6.3% |
| Drug Use For Unknown Indication |
4.3% |
| Pain |
2.9% |
| Systemic Lupus Erythematosus |
1.9% |
| Osteoporosis |
1.8% |
| Gastric Disorder |
1.8% |
| Arthritis |
1.4% |
| Prophylaxis |
1.2% |
| Depression |
1.1% |
| Multiple Myeloma |
1.0% |
| Gastritis |
0.9% |
| Hypothyroidism |
0.9% |
| Arthralgia |
0.8% |
| Contraception |
0.7% |
| Diabetes Mellitus |
0.7% |
| Antiretroviral Therapy |
0.6% |
| Osteoarthritis |
0.6% |
| Schizophrenia |
0.6% |
|
| Vomiting |
11.2% |
| Pneumonia |
10.1% |
| Pyrexia |
10.1% |
| Urinary Tract Infection |
9.0% |
| Systemic Lupus Erythematosus |
5.6% |
| Hypersensitivity |
4.5% |
| Myocardial Infarction |
4.5% |
| Pain |
4.5% |
| Thrombocytopenia |
4.5% |
| Viral Infection |
4.5% |
| Weight Decreased |
4.5% |
| Off Label Use |
3.4% |
| Skin Lesion |
3.4% |
| Tuberculosis |
3.4% |
| Viral Mutation Identified |
3.4% |
| Visual Acuity Reduced |
3.4% |
| Weight Increased |
3.4% |
| Allergic Bronchitis |
2.2% |
| Arthritis |
2.2% |
| Bursitis Infective |
2.2% |
|
| Interacting |
| Rheumatoid Arthritis |
58.3% |
| Drug Use For Unknown Indication |
25.0% |
| Neuralgia |
8.3% |
| Sciatica |
8.3% |
|
| Suicidal Ideation |
50.0% |
| Drug Interaction |
16.7% |
| Drug Level Increased |
16.7% |
| Loss Of Consciousness |
16.7% |
|
